Testosterone replacement is one molecule delivered six different ways, and the route changes almost everything about the experience except the drug. It changes how steady your levels are, how fast a dose error can be corrected, how much you pay, what safety warning applies, and what task you have to remember.
The pharmacology behind those differences is not complicated. Testosterone cypionate has a half-life of roughly eight days, so injection frequency determines the size of the peak-to-trough swing. Transdermal absorption varies several-fold between individuals, so gel dosing is empirical. Pellets release on a declining curve set at insertion, so the dose is fixed for months. Each of those facts produces a specific trade-off, and none of them makes one route correct for everyone.
The Verdict
The six routes side by side
Prices are typical US self-pay ranges for medication and dispensing. They exclude consults and labs, which are usually the larger line. Level-stability descriptions assume the dosing frequency listed.
| Route | How it is given | Level stability | What it asks of you | Typical drug cost | How fast a dose error can be fixed |
|---|---|---|---|---|---|
| Injection — intramuscular or subcutaneous | Testosterone cypionate or enanthate, weekly or split twice weekly | Peak 24–48h after the dose, trough before the next; splitting the weekly dose flattens the swing | One or two self-injections a week | $30–$100/mo for the drug | Dose changes take effect within a week |
| Injection — long-acting undecanoate | Oil-based depot, dosed roughly every 10 weeks in clinic | Very flat across the interval | Four to five clinic visits a year | Higher than generic cypionate; varies by payer | A dose cannot be walked back for weeks |
| Transdermal gel or cream | Applied daily to shoulders, upper arms or axilla | Steady once absorption is established, but absorption varies widely between men | Daily application plus a wash-and-cover routine | $40–$300/mo depending on branded vs compounded | Dose changes take effect within days |
| Subcutaneous pellets | Implanted in the hip or flank through a small incision, every 3–5 months | Supraphysiologic for the first weeks, then declining toward the end of the interval | Three to four in-office procedures a year | $500–$1,000 per insertion | A dose cannot be reduced without surgical removal |
| Oral undecanoate capsules | Twice daily with a fat-containing meal | Peaks and troughs within each day; food-dependent | Two doses a day, both with food | $200–$600/mo | Dose changes take effect within days |
| Nasal gel | Applied to each nostril two to three times daily | Short pulses rather than a steady level | Two or three doses a day | $300–$500/mo | Dose changes take effect within days |
Where injections lead
- Cost. Generic cypionate or enanthate runs $30–$100 a month, the lowest of any route by a wide margin.
- Reversibility. A dose that produces a high hematocrit or high estradiol can be reduced at the next injection, with the effect visible within one to two weeks.
- Predictability. The pharmacokinetics are well characterised, so a level drawn at a consistent point in the interval is straightforward to act on.
- Titration granularity. Dose can be adjusted in small increments, and frequency can be split further to flatten the curve without changing the weekly total.
- Independence from absorption variability. The full dose is delivered regardless of skin type, body fat, showering habits or application technique.
Where cream and gel lead
- No needles. For men with genuine needle aversion, this is the difference between adhering to therapy and abandoning it.
- Flatter daily curve. Daily application produces a smaller peak-to-trough swing than any injection interval, which tends to keep estradiol lower.
- Fast washout. Stopping the drug clears it within days, which is useful if an adverse effect appears or a decision is being reconsidered.
- Site and dose flexibility. Compounded creams allow fine dose adjustment, and scrotal application achieves target levels at lower doses in some men.
- No procedure and no clinic visit. Refills are a pharmacy transaction; nothing about the route requires an appointment.
Where pellets lead
- Adherence. There is no daily or weekly task to forget, which is the failure mode that ends more protocols than side effects do.
- No transfer risk. Nothing sits on the skin, so partners and children are not a consideration.
- Steady levels through the middle of the interval. Once past the early peak, the curve is flat for weeks at a time.
- Discretion and travel. Nothing to carry, refrigerate, or explain at a border; no controlled-substance prescription to transport.
- Fewer decisions. For a man who has already found a stable dose over a year or more on another route, the protocol becomes three or four appointments a year.
What each route asks you to monitor
The core monitoring set does not change with the route. What changes is which risk is most likely to appear and when the blood draw should be timed.
| Risk or effect | Which routes it applies to | How it is monitored |
|---|---|---|
| Erythrocytosis (rising hematocrit) | Highest with injections, particularly at longer intervals and higher peaks | Hematocrit at 3, 6 and 12 months, then annually; most prescribers act above roughly 54% |
| Secondary transfer to partners or children | Specific to gels and creams; carries an FDA boxed warning for virilization in children | Apply to covered skin, wash hands, allow drying time, cover the site with clothing |
| Site reaction, extrusion or infection | Specific to pellets; extrusion occurs in a small but consistent share of insertions | Wound checks after insertion; report drainage, swelling or a visible pellet |
| Blood pressure increase | Boxed warning on oral undecanoate and on the weekly subcutaneous auto-injector | Baseline and periodic blood-pressure monitoring; not a first choice in uncontrolled hypertension |
| Suppressed fertility | All exogenous testosterone routes; nasal gel suppresses the axis least because of its short pulses | Semen analysis if fertility matters; discuss hCG, a SERM, or sperm banking before starting |
| Estradiol elevation | Follows peak height, so highest with widely spaced injections and early-interval pellets | Sensitive LC/MS estradiol at 6–12 weeks; treat the pattern, not the number alone |
| Worsening of untreated sleep apnea | All routes | Screen for apnea before starting; treat it first if present |
| Prostate events | All routes | Baseline PSA, recheck at 3–12 months and annually; a rise over 1.4 ng/mL in a year warrants urology input |
Two boxed warnings are route-specific and worth knowing before a first prescription. Transdermal gels carry an FDA boxed warning for secondary exposure, because skin contact can transfer enough testosterone to cause virilization in children. Oral testosterone undecanoate and the weekly subcutaneous auto-injector carry boxed warnings for blood-pressure increase, which makes them a poor first choice in uncontrolled hypertension.
Contraindications that apply to every route
None of these is a delivery-method question. They apply to testosterone therapy in any form, and screening for them belongs before the route is chosen.
- Active breast cancer, or prostate cancer without specialist input
- An unevaluated prostate nodule or an elevated baseline PSA
- Baseline hematocrit above roughly 50%
- Untreated severe obstructive sleep apnea
- Uncontrolled heart failure, or a cardiovascular event within the past three to six months
- Known thrombophilia or prior unprovoked venous thromboembolism
- A desire to conceive in the near term — discuss hCG, a SERM, or sperm banking first
On cardiovascular safety, the TRAVERSE trial published in 2023 randomized roughly 5,200 middle-aged and older men with hypogonadism and cardiovascular risk to transdermal testosterone or placebo, and found no excess of major adverse cardiac events. It did find higher rates of pulmonary embolism, atrial fibrillation and acute kidney injury on testosterone. That evidence applies to the drug, not to any particular route.
How to decide
- First year, dose not yet settled. Favour a route you can adjust quickly — split injections or daily transdermal — so a lab finding at week eight can be acted on rather than waited out.
- Young children at home, or a partner who is or may become pregnant. Transfer risk is a real consideration; injections or pellets remove it.
- Needle aversion that has not resolved. Transdermal is the route that keeps men on therapy; a compounded cream also allows finer dose steps than a standard gel pump.
- Adherence is the repeated failure point. Pellets remove the task, and are a more reasonable choice once a stable dose is already known from another route.
- Fertility is a live concern. Consider whether testosterone is the right drug at all. Enclomiphene, clomiphene or hCG raise endogenous production without suppressing the axis, and nasal gel suppresses it least among testosterone routes.
- Uncontrolled blood pressure. Avoid oral undecanoate and the weekly auto-injector until it is managed.
Frequently Asked Questions
Which TRT delivery method should I choose?
It depends on which constraint binds hardest. If cost and dose control matter most, injections are the cheapest route and the easiest to titrate. If needles are not acceptable, daily gel or cream gives comparable levels with a transfer precaution to manage. If a daily or weekly task is the thing you will not sustain, pellets remove it entirely at the cost of reversibility and price. If fertility is a live concern, nasal gel suppresses the axis least, and a SERM or hCG-based approach may be a better conversation than testosterone at all.
Why do twice-weekly injections get recommended over weekly?
Testosterone cypionate has a half-life of roughly eight days, so a single weekly dose produces a peak within a day or two and a trough before the next injection. Splitting the same weekly total into two smaller doses roughly halves that swing. Men who report a mood and energy decline in the last two days of the interval frequently stop reporting it after the split. It is the same drug and the same monthly cost, with two injections instead of one.
Are pellets worth the cost?
For a man who has tried other routes and cannot sustain them, the convenience is real and the levels are steady across most of the interval. Two things make them a poor default for a first year. Levels run supraphysiologic in the first weeks and decline toward the end, which is the opposite of what titration wants. And a dose that turns out to be too high cannot be reduced without surgical removal, so a hematocrit or estradiol problem at week six has to be managed around rather than corrected.
How risky is testosterone gel around children?
Serious enough that the FDA requires a boxed warning. Skin-to-skin contact can transfer enough testosterone to cause virilization in children — early pubic hair, genital enlargement, advanced bone age — and some cases have not fully reversed. The precautions are practical rather than onerous: apply to skin that clothing will cover, wash hands immediately, let the site dry before dressing, and avoid contact with the site. Families with young children often choose injections for this reason alone.
Can I switch methods later?
Yes. Delivery route is not a permanent decision, and switching is routine. Many men start on gel and move to injections after seeing the cost difference, or start on injections and move to gel if injection anxiety does not settle. Expect a fresh level check 6–12 weeks after any switch, timed consistently relative to the dose, because the peak-to-trough shape changes with the route.
Does the delivery method change the monitoring schedule?
The schedule is broadly the same — levels, hematocrit, PSA and sensitive estradiol at 6–12 weeks after starting or changing, then every 6–12 months. What changes is the timing of the draw. On injections, draw at a consistent point in the interval, usually mid-interval or at trough, and record which. On gel, draw 2–8 hours after application. On pellets, a level at week 4 and again near the end of the interval shows the actual range rather than a single point on a declining curve.
Which method is best for keeping estradiol in range?
Aromatization follows peak testosterone concentration, so routes with lower peaks tend to produce lower estradiol. Split subcutaneous injections and daily transdermal application both keep peaks modest. Widely spaced injections and the first weeks after a pellet insertion produce the highest peaks and the highest estradiol. This is a reason to fix the delivery pattern before reaching for an aromatase inhibitor, which is over-prescribed relative to the evidence and carries its own risks at low estradiol.
Related
- Signs of low testosterone — which symptoms track the numbers
- Free vs total testosterone — how SHBG changes the answer
- TRT clinics compared — six physician-led programs on one rubric
- SHBG explained — the binding protein behind usable testosterone
- Doctor-led options — physician-supervised platforms compared